Patient tolerance to carbonic anhydrase inhibitors.
We evaluated carbonic anhydrase inhibitors in a crossover study with a placebo and random allocation of treatment administration. Drugs evaluated included acetazolamide tablets and Sequels, dichlorphenamide, ethoxzolamide, methazolamide, and an ascorbic acid placebo. The best tolerated drug was acetazolamide Sequels. Methazolamide was next. The least tolerated drugs were ethoxzolamide, acetazolamide tablets, and dichlorphenamide.
D000086:Acetazolamide / Q000627:therapeutic use; D000855:Anorexia / Q000139:chemically induced; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003221:Confusion / Q000139:chemically induced; D004005:Dichlorphenamide / Q000627:therapeutic use; D004341:Drug Evaluation; D005016:Ethoxzolamide / Q000627:therapeutic use; D005221:Fatigue / Q000139:chemically induced; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008704:Methazolamide / Q000627:therapeutic use
D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide; D004005:Dichlorphenamide; D008704:Methazolamide; D005016:Ethoxzolamide